Previous Close | 11.45 |
Open | 11.57 |
Bid | 11.38 x 0 |
Ask | 11.54 x 0 |
Day's Range | 11.45 - 11.57 |
52 Week Range | 9.27 - 14.41 |
Volume | |
Avg. Volume | 387 |
Market Cap | 305.824M |
Beta (5Y Monthly) | 0.24 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.02 |
Earnings Date | Nov 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences. Presentation Details: Event: Jefferies London Healthcare Conference in London, UKDate: November 16, 2023Time: Company Presentation at 5:00 a.m. ET / 10:00 a.m. GMT Ev
A week ago, Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) came out with a strong set of quarterly numbers that could...
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call Transcript November 6, 2023 Fennec Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.11. Operator: Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2023 Earnings and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. […]